Table 1.
Major phase 3 trials in the localized gastric cancer setting
| Trials | No. of patients | Treatment arms | HR for death (P value) | Survival Outcomes |
|---|---|---|---|---|
| Perioperative and preoperative chemotherapy | ||||
| Cunningham et al. 9 (MAGIC) | 503 | ECF →Surgery →ECF versus Surgery | 0.75 (0.009) | 5‐year OS: 36.3% versus 23% |
| Schuhmacher et al. 13(EORTC 40954) | 144 | CFL →Surgery (only preoperative CT) versus Surgery | 0.84 (0.466) | 2‐year OS: 72.7% versus 69.9% |
| Al‐Batran et al. 16(FLOT4‐AIO) | 716 | ECF/ECX→Surgery →ECF/ECX versusFLOT→Surgery →FLOT | 0.77 (0.012) | 3‐year OS: 48% versus 57% |
| Postoperative chemoradiotherapy | ||||
| Macdonald et al. 10, Smalley et al. 17(INT‐ 0116) | 556 | Surgery →FL/CTRT (45 Gy+FL)/FL versus Surgery | 1.32 (0.0046) | 3‐year OS: 50% versus 41% (OS: 36 versus 27 months) |
| Park et al. 18 (ARTIST) | 458 | Surgery →XP/XRT/XP versus Surgery →XP | 1.130 (0.5272),HR for relapse: 0.740 (0.0922) | 5‐year OS: 75% versus 73%,N+ pts: 3‐year DFS: 76% versus 72% |
| Verheij et al. 19 (CRITICS) | 788 | ECX or EOX → Surgery → XPRT versus ECX or EOX→ Surgery → ECX or EOX | NR (0.99) | 5‐year OS: 40.9% versus 40.8% |
| Postoperative chemotherapy | ||||
| Sasako et al. 21 (ACTS‐GC) | 1059 | Surgery → S‐1 versus Surgery | 0.669 (0.003) | 5‐year OS: 71.7% versus 61.1% |
| Noh et al. 22 (CLASSIC) | 1035 | Surgery → XELOX versus Surgery | 0.66 (0.0015),HR for relapse: 0.58 (<0.0001) | 5‐year OS: 78% versus 69%,5‐year DFS: 68% versus 53% |
HR, Hazard ratio; OS, Overall survival; 5‐FU, 5‐Fluorouracil; ECF, Epirubicin, Cisplatin and 5‐FU; CF, Cisplatin and 5‐FU; CFL, Cisplatin, 5‐FU and leucovorin; CT, Chemotherapy; ECX, Epirubicin, Cisplatin and Capecitabine; FLOT, Docetaxel, Oxaliplatin and 5‐FU/leucovorin; FL, 5‐FU and leucovorin; CTRT, Chemoradiotherapy; XP, Capecitabine and Cisplatin; XRT, Capecitabine and radiotherapy; DFS, Disease‐free survival; EOX, Epirubicin, Oxaliplatin and Capecitabine; XPRT, Capecitabine, Cisplatin and radiotherapy; NR, Not reported; XELOX, Capecitabine and Oxaliplatin.